Review Article
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Table 2
Selected clinical
trials of gefitinib. NSCLC, Non-small
cell lung cancer; OS, overall survival; ORR, overall response
rate; C/P, carboplatin/paclitaxel; PFS, progression free survival; EGFR, epidermal growth factor receptor.
| | Malignancy | Regimen | Number of patients | Results | Comments |
| | NSCLC | Gefitinib vs. placebo
[19] | 1692 pts
Second-line or third-line
treatment for patients with locally advanced or metastatic NSCLC | Gefitinib: OS (5.6 mo)
Placebo: OS (5.1 mo) | No significant improvement in
OS ()
Subgroup analysis showed
significantly longer survival in never-smokers and Asian patients |
| | NSCLC | Gefitinib vs.
Carboplatin/paclitaxel (C/P)
[23] | 1,217 pts
Previously untreated stage
IIIB/IV NSCLC, never- or light ex-smokers, adenocarcinoma histology | Gefitinib: ORR (43%)
OS (18.6 mo) C/P:
ORR (32%) OS (17.3 mo)
= .0001 | No OS difference
PFS longer for gefitinib than
C/P in EFGR mutation positive patients ()
PFS longer with C/P in
mutation negative patients () |
|
|
